HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $134 Price Target

+0.65% Pre

BioNTech

BNTX

0.00

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ: BNTX) with a Buy and maintains $134 price target.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Pre-Bell Movers | MDB Appreciates Sharply by 23.2%; Here Are 20 Stocks Moving Premarket

The Bull Case For BioNTech (BNTX) Could Change Following Higher Guidance And Oncology Progress – Learn Why

Trading Halt: Halt status updated at 7:45:00 AM ET: Quotation Resumption: News and Resumption Times

BMO Capital Maintains Outperform on Amgen, Raises Price Target to $372

BioNTech Minimum Condition in CureVac Exchange Offer Has Been Satisfied

Crude Oil Gains 1%; Macy's Reports Strong Q3 Results

Has Arcutis’ 106% 2025 Surge Outrun Its DCF Value and Sales Multiple?

Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss